exhaustion gap and reversal bar ?, page-34

Hi trader,

And you maybe a trader, I do not know but what I DO know is the fact that you do not find many Biotas on the ASX.

We have a kind of a one or very few chances in a live time to make EXTRAORDINARY returns from a Biotech company with all the facts written on the wall.

Would you want to sell out at a meagre $3.40 or so when you can get the $10 mark if you can wait another 12 months???

Because thats where we are heading with Biota this time imho, its like we are back to the time when Relenza first hit the markets and Biota was reaching a shareprice of more the $10 per share.

The only difference now is the fact that we have far more drugs in the pipeline , an already healthy cash balance , a proven product for many years, and the new Relenza ( Lani) hitting the markets in the next 6 months or so.

The only difference is that the patents of Relenza will run out in the next 4 year or so , but the Lani will take over.

So why sell now when all points to a much higher share price????
Even the market dept of buying and selling is every day in our favour, that alone should give you an indication how the wider market values Biota right now.

Biota is a company that is now at the cross roads of change in a much bigger company.
The organic growth alone will soon be a thing of the past, as the high amounts of surplus cash will be used to aquire projects that will fit the Biota market strategie.

And we know how many Biotechs out there have good products but struggle always for cash to get those products to the markets.
Biota can easily snap the good ones up, and add them to their portfolio.
And PC has said that this is the way Biota has chooses to use its tremendous surplus cashflow.

This alone will completely change the ball game of this company and can make this biotech grow much faster into something much bigger.

So if you think about selling now , think again, because you end up paying much more later , to still be part of this huge upside of this company.

I will be holding for a much higher shareprice before I even contemplate selling some, because I feel that we have only touched the beginning of a BIG re-rating in this undervalued biotech company.

good luck

jojo